{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:37:05Z","timestamp":1760783825365},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T00:00:00Z","timestamp":1403568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.taap.2014.06.002","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T20:18:16Z","timestamp":1402949896000},"page":"230-239","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety"],"prefix":"10.1016","volume":"279","author":[{"given":"Patricia C.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Sleeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlon","family":"Rebelatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jane","family":"Hinrichs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorin","family":"Roskos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Towers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"McKeever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.taap.2014.06.002_bb0005","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1164\/rccm.201004-0654OC","article-title":"Segmental allergen challenge alters multimeric structure and function of surfactant protein D in humans","volume":"183","author":"Atochina-Vasserman","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.taap.2014.06.002_bb0010","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/ard.2010.146225","article-title":"Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-\u03b1, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.taap.2014.06.002_bb0015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","article-title":"Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.taap.2014.06.002_bb0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clim.2010.02.017","article-title":"The molecular basis of pulmonary alveolar proteinosis","volume":"135","author":"Carey","year":"2010","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.taap.2014.06.002_bb0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.bmb.a070012","article-title":"Lymph Flow in the Lungs","volume":"19","author":"Courtice","year":"1963","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.taap.2014.06.002_bb0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.8171324","article-title":"Involvement of granulocyte\u2013macrophage colony stimulating factor in pulmonary homeostasis","volume":"264","author":"Dranoff","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.taap.2014.06.002_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.etp.2006.07.003","article-title":"A review of background findings in cynomolgus monkeys (Macaca fascicularis) from three different geographical origins","volume":"58","author":"Drevon-Gaillot","year":"2006","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.taap.2014.06.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2014.02.001","article-title":"Challenges for inhaled drug discovery and development: induced alveolar macrophage responses","author":"Forbes","year":"2014","journal-title":"Adv. Drug Deliv. Rev"},{"issue":"4","key":"10.1016\/j.taap.2014.06.002_bb0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Scleroderma Lung Study Research Group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.taap.2014.06.002_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ppul.10044","article-title":"Serum KL-6 levels in pediatric patients: reference values for children and levels in pneumonia, asthma, and measles patients","volume":"33","author":"Imai","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.taap.2014.06.002_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1465-9921-12-32","article-title":"KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome","volume":"12","author":"Kondo","year":"2011","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.taap.2014.06.002_bb0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2478\/v10042-009-0028-9","article-title":"Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis","volume":"47","author":"Kucejko","year":"2009","journal-title":"Folia Histochem. Cytobiol."},{"key":"10.1016\/j.taap.2014.06.002_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jat.2950","article-title":"Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for inhaled drug development","volume":"34","author":"Lewis","year":"2014","journal-title":"J. Appl. Toxicol."},{"issue":"1","key":"10.1016\/j.taap.2014.06.002_bb0070","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1476-5381.2012.02173.x","article-title":"Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis","volume":"168","author":"Minter","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.taap.2014.06.002_bb0075","first-page":"47","article-title":"Serum KL-6 as a novel disease marker in adolescent and adult cystic fibrosis","volume":"26","author":"Ohshimo","year":"2009","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"4","key":"10.1016\/j.taap.2014.06.002_bb0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jcf.2010.03.011","article-title":"Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis","volume":"9","author":"Olesen","year":"2010","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.taap.2014.06.002_bb0085","first-page":"321","article-title":"Granulocyte\u2013macrophage colony-stimulating factor and pulmonary surfactant homeostasis","volume":"110","author":"Reed","year":"1998","journal-title":"Proc. Assoc. Am. Physicians"},{"key":"10.1016\/j.taap.2014.06.002_bb0090","doi-asserted-by":"crossref","first-page":"L1164","DOI":"10.1152\/ajplung.2000.278.6.L1164","article-title":"Distinct changes in pulmonary surfactant homeostasis in common beta-chain and GM-CSF-deficient mice","volume":"278","author":"Reed","year":"2000","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.taap.2014.06.002_bb0095","doi-asserted-by":"crossref","first-page":"9565","DOI":"10.1073\/pnas.92.21.9565","article-title":"Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte\u2013macrophage colony-stimulating factor and interleukins 3 and 5","volume":"92","author":"Robb","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.taap.2014.06.002_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.201001-0008OC","article-title":"Patient-derived granulocyte\/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates","volume":"182","author":"Sakagami","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.taap.2014.06.002_bb0105","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1073\/pnas.91.12.5592","article-title":"Granulocyte\/macrophage colony-stimulating factor deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology","volume":"91","author":"Stanley","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2014.06.002_bb0110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev.physiol.64.090601.113847","article-title":"GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense","volume":"64","author":"Trapnell","year":"2002","journal-title":"Annu. Rev. Physiol."},{"issue":"11","key":"10.1016\/j.taap.2014.06.002_bb0115","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood-2008-05-155689","article-title":"Granulocyte\/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects","volume":"113","author":"Uchida","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.taap.2014.06.002_bb0125","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","article-title":"Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials","volume":"49","author":"Wang","year":"2009","journal-title":"J. Clin. Pharm."},{"issue":"8","key":"10.1016\/j.taap.2014.06.002_bb0120","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/0091270011412964","article-title":"Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis","volume":"52","author":"Wang","year":"2012","journal-title":"J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.taap.2014.06.002_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1378\/chest.09-1484","article-title":"Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury","volume":"137","author":"Ware","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.taap.2014.06.002_bb0135","doi-asserted-by":"crossref","first-page":"L379","DOI":"10.1152\/ajplung.2001.280.3.L379","article-title":"GM-CSF regulates protein and lipid catabolism by alveolar macrophages","volume":"280","author":"Yoshida","year":"2001","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X14002257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X14002257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T15:29:19Z","timestamp":1565537359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X14002257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0041008X14002257"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2014.06.002","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2014.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}